Biomarkers may be predictive of patient response to bladder cancer treatments

“Our work indicates that these genetic signatures may prove to be tremendously valuable in predicting immunotherapy response in patients with bladder cancer, but also other tumor types," says Dan Theodorescu, MD, PhD.

Dr. Stephanie Berg on latest pivotal trials in mCSPC

Stephanie Berg, MD, highlights the key findings of the PEACE-1 and ARASENS trials in patients with metastatic castration-sensitive prostate cancer.

Video: Dr. Amy Krambeck performs HoLEP

Watch Amy E. Krambeck, MD, perform holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.